I-131 In the Management of Differentiated thyroid Cancer – an Update on Current Recommendations and Practices

Protein and Lipid Concentrations in Patients with Differentiated Thyroid Cancer Treated with Radioactive Iodine-131 / Koncentracija Proteina I Lipida Kod Pacijenata Sa Diferentovanim Karcinomom Štitaste Žlezde Koji Su Lečeni Radioaktivnim Jodom-131

“…Iodine-131 is used for the ablation of remnant thyroid tissue or for the treatment of iodine-avid metastasis (11). For the optimal accumulation of 131-I in differentiated thyroid tissue, an elevated TSH concentration is required (12).…”

10.5937/mckg48-4067 = Differentiated thyroid carcinomas: Epidemiology, etiopathogenesis, diagnostics and therapy

“…Diferentovani (ili dobrodiferentovani) karcinomi štitaste žlezde (DTC) čine više od 90% svih tireoidnih tumora i obuhvataju papilarne i folikularne karcinome. Osnovna karakteristika dobrodiferentovanih tireoidnih carcinoma je da tumorske ćelije zadržavaju izvesna biološka svojstva tireocita, kao što su preuzimanje i koncentrisanje joda (4). Papilarni karcinomi su najfrekventniji tumori štitaste žlezde (oko 75%) (5).…”

Impact of the amount of liquid intake on the dose rate of patients treated with radioiodine

“…The management of DCT is total thyroidectomy to remove the thyroid cancer cells followed by radioiodine ( 131 I) ablation as an adjuvant therapy to destroy the remnant thyroid cancer cells. [ 3 4 5 6 7 8 ] Using radioactive iodine for thyroid remnant ablation and metastasis treatment in patients with DTC is still a well-accepted and effective method after more than six decades. Emitting 806 keV beta particles, 131 I can destroy the remnant thyroid tissue and remaining cancer cells.…”